Clinical Studies Using IMT Other Than in Brain Tumors
| Study | Year | No. of patients | Tumor type | Sensitivity (%) | Remarks and findings |
|---|---|---|---|---|---|
| Flamen (90) | 1999 | 11 | Head and neck | 91 | For primary tumors; ∼60% for nodal spread |
| Jager (37) | 1998 | 20 | Various types | — | Feasible in breast cancer, lung cancer, sarcoma, and lymphoma |
| Boni (109) | 1997 | 7 | Melanoma | 37 | For lesion detection |
| Jager (110) | 2000 | 22 | Carcinoid | 43–60 | Correlation with secretory activity |
| Jager (42) | 2000 | 32 | Sarcoma | 100 | 88% specificity for differentiation between benign and malignant; correlation with proliferation |
| Jager (96) | 2000 | 17 | Lung cancer | 94 | For primary tumors; 60% for mediastinal lesions |